Clinical Research Directory
Browse clinical research sites, groups, and studies.
Psilocybin for Methamphetamine Use Disorder
Sponsor: Peter Hendricks
Summary
This trial tests whether psilocybin-assisted treatment can help adults stop using methamphetamine. Participants receive a single oral dose of psilocybin during a supervised session, paired with brief cognitive behavioral therapy, and are followed for up to six months. The study is supported by the HEAL Initiative (https://www.nih.gov/heal).
Official title: Psilocybin in the Treatment of Methamphetamine Use Disorder
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
42
Start Date
2027-02-01
Completion Date
2032-02-01
Last Updated
2026-08-19
Healthy Volunteers
No
Conditions
Interventions
Psilocybin (single oral capsule administered at one of two dose levels, Dose A or Dose B; specific doses withheld during conduct).
The specific doses (in mg) are intentionally omitted from this registration during the conduct of the trial to preserve masking and reduce expectancy effects. The doses will be disclosed when results are reported after primary completion, by which point participants have been debriefed.
Manualized cognitive behavioral therapy platform (2 preparation + 2 integration sessions).
Manualized CBT, adapted from Hendricks et al. (2026; https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848757)
Locations (1)
University of Alabama at Birmingham
Birmingham, Alabama, United States